McKesson wins new two-year Veterans Affairs contract

Thu Apr 12, 2012 4:30am IST

Related Topics

Stocks

   

(Reuters) - Pharmaceutical wholesaler McKesson Corp on Wednesday said it was selected by the U.S. Department of Veterans Affairs to continue as the VA's prime pharmaceutical supplier for at least two more years.

News of the contract, which includes options for up to three two-year extensions, sent shares of McKesson up more than 4 percent in after hours trading.

The new agreement, valued by the VA at over $31.6 billion, calls for McKesson to supply all of the VA's more than 700 medical centers and outpatient clinics, as well as its seven consolidated mail outpatient pharmacies.

"Over the past eight years, McKesson has partnered with the VA to serve the healthcare needs of America's veterans," Paul Julian, the company's executive vice president and group president, said in a statement.

The VA, which estimated savings of about $3.26 billion through the life of the contract, said the new agreement goes into effect on May 10.

Shares of McKesson, which closed at $87.90 on the New York Stock Exchange, were trading at $91.89 after hours.

(Reporting By Deena Beasley, editing by M.D. Golan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

Walk for Fitness

Walk for Fitness

Walking is the superfood of fitness, experts say.  Full Article 

Ebola Outbreak

Ebola Outbreak

Bill Gates warns Ebola could spread beyond West Africa.  Full Article | Related Story 

Birth Control

Birth Control

Long-acting reversible contraceptives best for teens: pediatricians.  Full Article 

Trial Goal Met

Trial Goal Met

Seattle Genetics and Takeda's cancer drug meets main trial goal.  Full Article 

Childhood Obesity

Childhood Obesity

Antibiotics in infancy may be linked to childhood obesity: study.  Full Article 

MERS Update

MERS Update

Austria reports first MERS case in Saudi national: media.  Full Article 

Sinusitis Drug

Sinusitis Drug

Sanofi-Regeneron drug has positive trial results in chronic sinusitis.  Full Article